Free Trial

Dominari (DOMH) Competitors

Dominari logo
$4.99 +0.21 (+4.39%)
As of 07/11/2025 04:00 PM Eastern

DOMH vs. XOMA, VNDA, VSTM, CDXS, SGMO, AGEN, IRWD, ACHV, FBIO, and CRIS

Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Codexis (CDXS), Sangamo Therapeutics (SGMO), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), and Curis (CRIS). These companies are all part of the "biotechnology" industry.

Dominari vs. Its Competitors

XOMA Royalty (NASDAQ:XOMA) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

XOMA Royalty currently has a consensus target price of $69.50, suggesting a potential upside of 156.08%. Given XOMA Royalty's stronger consensus rating and higher probable upside, analysts plainly believe XOMA Royalty is more favorable than Dominari.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA Royalty
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dominari
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

95.9% of XOMA Royalty shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 9.1% of XOMA Royalty shares are owned by company insiders. Comparatively, 33.0% of Dominari shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

XOMA Royalty has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

In the previous week, XOMA Royalty had 1 more articles in the media than Dominari. MarketBeat recorded 2 mentions for XOMA Royalty and 1 mentions for Dominari. Dominari's average media sentiment score of 1.87 beat XOMA Royalty's score of 1.23 indicating that Dominari is being referred to more favorably in the news media.

Company Overall Sentiment
XOMA Royalty Positive
Dominari Very Positive

XOMA Royalty has a net margin of -13.04% compared to Dominari's net margin of -167.73%. XOMA Royalty's return on equity of -12.43% beat Dominari's return on equity.

Company Net Margins Return on Equity Return on Assets
XOMA Royalty-13.04% -12.43% -4.85%
Dominari -167.73%-91.67%-77.80%

XOMA Royalty has higher revenue and earnings than Dominari. XOMA Royalty is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA Royalty$28.49M11.40-$13.82M-$1.15-23.60
Dominari$18.15M4.02-$14.70M-$4.50-1.11

Summary

XOMA Royalty beats Dominari on 13 of the 16 factors compared between the two stocks.

Get Dominari News Delivered to You Automatically

Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DOMH vs. The Competition

MetricDominariMED IndustryMedical SectorNASDAQ Exchange
Market Cap$70M$2.74B$5.62B$9.10B
Dividend YieldN/A1.79%5.24%4.00%
P/E Ratio-1.119.4228.1320.27
Price / Sales4.02714.13428.6398.72
Price / CashN/A165.3637.4658.16
Price / Book0.874.608.045.49
Net Income-$14.70M$31.26M$3.18B$250.45M
7 Day Performance-5.31%4.80%3.62%4.78%
1 Month Performance-5.13%5.42%4.05%7.67%
1 Year Performance159.90%-4.36%30.00%16.43%

Dominari Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DOMH
Dominari
1.1191 of 5 stars
$4.99
+4.4%
N/A+164.0%$70M$18.15M-1.114
XOMA
XOMA Royalty
4.0096 of 5 stars
$25.37
+0.7%
$69.50
+173.9%
+3.7%$302.12M$28.49M-21.9510Positive News
VNDA
Vanda Pharmaceuticals
4.7762 of 5 stars
$4.68
-0.8%
$16.50
+252.6%
-18.3%$276.68M$198.77M-6.26290
VSTM
Verastem
3.1464 of 5 stars
$4.19
+0.8%
$13.38
+219.6%
+57.0%$229.75M$10K-1.3150News Coverage
CDXS
Codexis
3.4984 of 5 stars
$2.42
-1.0%
$11.00
+355.5%
-8.3%$200.91M$59.35M-2.45250Positive News
SGMO
Sangamo Therapeutics
2.7236 of 5 stars
$0.52
-3.8%
$4.50
+763.7%
+12.2%$121.48M$57.80M-1.34480Positive News
AGEN
Agenus
4.3151 of 5 stars
$4.42
-3.3%
$14.00
+216.7%
-54.1%$121.20M$103.46M-0.51440News Coverage
IRWD
Ironwood Pharmaceuticals
4.7463 of 5 stars
$0.75
+4.2%
$4.78
+540.3%
-89.0%$120.39M$351.41M-3.72220News Coverage
Positive News
ACHV
Achieve Life Sciences
2.6241 of 5 stars
$2.20
-2.9%
$14.33
+553.0%
-52.1%$76.49MN/A-1.6520
FBIO
Fortress Biotech
3.0277 of 5 stars
$1.85
-0.8%
$21.00
+1,038.2%
-4.1%$54.56M$57.67M-0.83170News Coverage
CRIS
Curis
2.4057 of 5 stars
$2.30
-1.1%
$17.00
+640.7%
-73.6%$24.01M$10.91M-0.3760

Related Companies and Tools


This page (NASDAQ:DOMH) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners